Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP2 + Nivolumab vs Ipilimumab + Nivolumab in Metastatic Uveal Melanoma
NCT06581406Phase 3Recruiting
- Sponsor
- Replimune Group, Inc.
- Start
- Dec 2024
- Primary completion
- Jan 2030
- Modality
- Gene Editing, Antibody Conjugates, Gene Silencing
- Countries
- 3
01
Overview
A Phase 3 trial of sturlimogene erparepvec in Uveal melanoma (UM), sponsored by Replimune Group, Inc.. Started Dec 2024; status: recruiting.
02
Drugs
sturlimogene erparepvec
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT06581406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581406.